Shanghai Pharmaceutical: Pralabalin Capsules Obtained Thai Drug Registration Certificate

Shanghai Pharmaceutical announced that its subsidiary, Shang Yao Thailand Co., Ltd., has received a drug registration certificate from the Thai Food and Drug Administration for its Pregabalin capsules. The drug is mainly used for the treatment of post-herpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, neuropathic pain caused by spinal cord injury, and as adjunctive therapy for epilepsy. The Pregabalin capsules in 50mg, 75mg, and 150mg specifications have been approved for marketing. As of the announcement date, the company has invested approximately 2.19 million RMB in research and development expenses for this drug in the Southeast Asian market. The total sales of Pregabalin capsules in all available specifications in the Thai market in 2024 were 46.63 million US dollars.